Literature DB >> 9052859

Selective in vivo recruitment of the phosphatidylinositol phosphatase SHIP by phosphorylated Fc gammaRIIB during negative regulation of IgE-dependent mouse mast cell activation.

D C Fong1, O Malbec, M Arock, J C Cambier, W H Fridman, M Daëron.   

Abstract

We demonstrated previously that the low-affinity IgG receptors Fc gammaRIIB, which are coexpressed with the high-affinity IgE receptors Fc epsilonRI in mouse mast cells, can inhibit IgE-induced release of inflammatory mediators and cytokines by these cells. Inhibition was found to require the coaggregation of the two receptors and to depend on the presence of a tyrosine-based inhibition motif (ITIM) in the intracytoplasmic domain of Fc gammaRIIB. We report here that the coaggregation with Fc gammaRIIB does not prevent Fc epsilonRI from triggering activation signals in BMMC and induces the tyrosine phosphorylation of Fc gammaRIIB. Phosphorylated ITIM peptides bound in vitro to three SH2 domain-containing phosphatases present in BMMC lysates: the phosphotyrosine phosphatases SHP-1 and SHP-2. and the inositolphosphate phosphatase SHIP. Using BMMC generated from the SHP-1-deficient motheaten mice, SHP-1 was found to be dispensable for inhibition of mast cell activation. When analyzed for in vivo association, SHIP coprecipitated with phosphorylated Fc gammaRIIB, whereas SHP-1 or SHP-2 did not. These observations altogether indicate that Fc epsilonRI actively participates in its own regulation and that the mechanisms by which Fc gammaRIIB inhibit cell activation might be different in mast cells and in B-cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9052859     DOI: 10.1016/s0165-2478(96)02654-5

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  19 in total

Review 1.  Molecular underpinning of B-cell anergy.

Authors:  Yuval Yarkoni; Andrew Getahun; John C Cambier
Journal:  Immunol Rev       Date:  2010-09       Impact factor: 12.988

Review 2.  Chimeric human fcgamma-allergen fusion proteins in the prevention of allergy.

Authors:  Ke Zhang; Daocheng Zhu; Christopher Kepley; Tetsuya Terada; Andrew Saxon
Journal:  Immunol Allergy Clin North Am       Date:  2007-02       Impact factor: 3.479

Review 3.  Tyrosine phosphatase SHP-1 in allergic and anaphylactic inflammation.

Authors:  Zhou Zhu; Sun Young Oh; You Sook Cho; Li Zhang; Yoon-Keun Kim; Tao Zheng
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

Review 4.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

5.  The paired Ig-like receptor PIR-B is an inhibitory receptor that recruits the protein-tyrosine phosphatase SHP-1.

Authors:  M Bléry; H Kubagawa; C C Chen; F Vély; M D Cooper; E Vivier
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

6.  A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation.

Authors:  Daocheng Zhu; Christopher L Kepley; Min Zhang; Ke Zhang; Andrew Saxon
Journal:  Nat Med       Date:  2002-05       Impact factor: 53.440

Review 7.  FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications.

Authors:  Kenneth G C Smith; Menna R Clatworthy
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

Review 8.  Fc receptors and their role in immune regulation and autoimmunity.

Authors:  Toshiyuki Takai
Journal:  J Clin Immunol       Date:  2005-01       Impact factor: 8.317

Review 9.  Calcium signalling and cell-fate choice in B cells.

Authors:  Andrew M Scharenberg; Lisa A Humphries; David J Rawlings
Journal:  Nat Rev Immunol       Date:  2007-10       Impact factor: 53.106

Review 10.  Regulation of hematopoietic cell function by inhibitory immunoglobulin G receptors and their inositol lipid phosphatase effectors.

Authors:  Carol T Cady; Jeffrey S Rice; Vanessa L Ott; John C Cambier
Journal:  Immunol Rev       Date:  2008-08       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.